Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $188.97 | 11 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech USA, Inc. | $156.40 | 10 | $0 (2022) |
| PFIZER INC. | $32.57 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $32.57 | 1 | PFIZER INC. ($32.57) |
| 2022 | $39.84 | 2 | Genentech USA, Inc. ($39.84) |
| 2021 | $116.56 | 8 | Genentech USA, Inc. ($116.56) |
All Payment Transactions
11 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/02/2024 | PFIZER INC. | PREVNAR 20 (Biological), COMIRNATY, ABRYSVO | Food and Beverage | In-kind items and services | $32.57 | General |
| Category: VACCINES | ||||||
| 02/16/2022 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $15.02 | General |
| Category: Virology & Specialty Care | ||||||
| 01/21/2022 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $24.82 | General |
| Category: Virology & Specialty Care | ||||||
| 12/23/2021 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $22.22 | General |
| Category: Virology & Specialty Care | ||||||
| 11/03/2021 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $18.32 | General |
| Category: Virology & Specialty Care | ||||||
| 10/12/2021 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $8.50 | General |
| Category: Virology & Specialty Care | ||||||
| 10/06/2021 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $9.11 | General |
| Category: Virology & Specialty Care | ||||||
| 02/24/2021 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $9.07 | General |
| Category: Virology & Specialty Care | ||||||
| 02/05/2021 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $21.85 | General |
| Category: Virology & Specialty Care | ||||||
| 01/27/2021 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $13.34 | General |
| Category: Virology & Specialty Care | ||||||
| 01/26/2021 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $14.15 | General |
| Category: Virology & Specialty Care | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 173 | 175 | $40,583 | $11,225 |
| 2022 | 6 | 158 | 160 | $37,859 | $12,034 |
| 2021 | 8 | 206 | 207 | $28,955 | $10,470 |
| 2020 | 3 | 81 | 83 | $17,884 | $5,456 |
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 83 | 84 | $22,208 | $5,354 | 24.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 22 | 22 | $7,223 | $2,001 | 27.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 24 | 24 | $4,941 | $1,697 | 34.4% |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | Office | 2023 | 22 | 23 | $2,832 | $1,156 | 40.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 11 | 11 | $3,213 | $978.16 | 30.4% |
| 81002 | Urinalysis, manual test | Office | 2023 | 11 | 11 | $165.00 | $37.51 | 22.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 64 | 65 | $15,194 | $4,741 | 31.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 20 | 21 | $7,003 | $2,038 | 29.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 25 | 25 | $6,512 | $2,026 | 31.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 12 | 12 | $4,599 | $1,350 | 29.3% |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | Office | 2022 | 20 | 20 | $2,000 | $1,012 | 50.6% |
| 87635 | Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2022 | 17 | 17 | $2,550 | $866.65 | 34.0% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 35 | 35 | $8,904 | $3,416 | 38.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 33 | 33 | $6,720 | $2,240 | 33.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 16 | 17 | $3,921 | $1,601 | 40.8% |
| 87635 | Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2021 | 27 | 27 | $4,860 | $1,385 | 28.5% |
| 0012A | Adm sarscov2 100mcg/0.5ml2nd | Office | 2021 | 24 | 24 | $2,400 | $828.28 | 34.5% |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | Office | 2021 | 13 | 13 | $1,300 | $667.03 | 51.3% |
| 0011A | Adm sarscov2 100mcg/0.5ml1st | Office | 2021 | 17 | 17 | $850.00 | $332.01 | 39.1% |
| 91301 | Sarscov2 vac 100mcg/0.5ml im | Office | 2021 | 41 | 41 | $0.41 | $0.41 | 100.0% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 34 | 34 | $7,951 | $2,411 | 30.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 35 | 37 | $7,778 | $2,372 | 30.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 12 | 12 | $2,155 | $672.28 | 31.2% |
About Mandy Page, PA
Mandy Page, PA is a Medical healthcare provider based in Medway, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/25/2010. The National Provider Identifier (NPI) number assigned to this provider is 1265732374.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Mandy Page, PA has received a total of $188.97 in payments from pharmaceutical and medical device companies, with $32.57 received in 2024. These payments were reported across 11 transactions from 2 companies. The most common payment nature is "Food and Beverage" ($188.97).
As a Medicare-enrolled provider, Page has provided services to 618 Medicare beneficiaries, totaling 625 services with total Medicare billing of $39,185. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Practice Information
- Specialty Medical
- Other Specialties Physician Assistant
- Location Medway, MA
- Active Since 10/25/2010
- Last Updated 11/26/2024
- Taxonomy Code 363AM0700X
- Entity Type Individual
- NPI Number 1265732374
Products in Payments
- Xofluza (Drug) $156.40
- PREVNAR 20 (Biological) $32.57
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.